Cyfuse Biomedical K.K.

Equities

4892

JP3311800001

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
706 ^JPY	+0.86%		+0.57%	-7.35%

2023	Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	CI
2023	Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 28-FEB-2023.	CI

Cyfuse Biomedical K.K. has completed an IPO in the amount of Ã‘2.477466 billion.

December 01, 2022 at 12:00 am EST

Cyfuse Biomedical K.K. has completed an IPO in the amount of Ã‘2.477466 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,529,300
PriceRange: Ã‘1620
Discount Per Security: Ã‘129.6
Transaction Features: Sponsor Backed Offering

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	CYFUSE BIOMEDICAL K.K.	706 JPY	+0.86%	+0.57%	35.06M
	CYBERDYNE INC.	201 JPY	-0.50%	-4.74%	271M

Latest news about Cyfuse Biomedical K.K.

Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	23-05-31	CI
Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 28-FEB-2023.	23-02-27	CI
Cyfuse Biomedical K.K. has completed an IPO in the amount of Ã‘2.477466 billion.	22-12-01	CI
Cyfuse Biomedical K.K. has filed an IPO.	22-10-27	CI

Chart Cyfuse Biomedical K.K.

Duration

Period

More charts

Company Profile

Cyfuse Biomedical KK is a Japan-based company mainly engaged in the research, development, manufacture and sale of cell products. The Company is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The Company is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The Company is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CYFUSE BIOMEDICAL K.K.	-7.35%	35.06M
MODERNA, INC.	+12.08%	42.68B
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+47.07%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research